Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
5,457
Views
34
CrossRef citations to date
0
Altmetric
Original Research

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

Devayani Machirajua Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Melanie Wieckena Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;b Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany;c Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyView further author information
,
Nina Langa Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Ingrid Hülsmeyera Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Jasmin Rotha Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Timo E. Schanka Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Rosa Eurichd Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Niels Halamad Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
,
Alexander Enka Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyView further author information
&
Jessica C. Hassela Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GermanyCorrespondence[email protected]
View further author information
 show all
Article: 1926762 | Received 08 Mar 2021, Accepted 01 May 2021, Published online: 25 May 2021

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long & Richard A. Scolyer. (2023) Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. OncoImmunology 12:1.
Read now
Ernesto Rossi, Ilaria Grazia Zizzari, Alessandra Di Filippo, Anna Acampora, Monica Maria Pagliara, Maria Grazia Sammarco, Maurizio Simmaco, Luana Lionetto, Andrea Botticelli, Emilio Bria, Paolo Marchetti, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari & Marianna Nuti. (2022) Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Human Vaccines & Immunotherapeutics 18:3.
Read now

Articles from other publishers (32)

Yao Gao, Yao Wang, Yueyue Luo, Yong Zhang, Saiqi Wang, Xiance Tang, Peng Qin, Benling Xu, Quanli Gao & Tiepeng Li. (2024) Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors. Melanoma Research.
Crossref
Jiabao Tian & Camelia Quek. (2024) Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses. International Journal of Molecular Sciences 25:8, pages 4243.
Crossref
Alain Gelibter, Angela Asquino, Lidia Strigari, Ilaria Grazia Zizzari, Lucrezia Tuosto, Fabio Scirocchi, Angelica Pace, Marco Siringo, Elisa Tramontano, Serena Bianchini, Filippo Bellati, Andrea Botticelli, Donatella Paoli, Daniele Santini, Marianna Nuti, Aurelia Rughetti & Chiara Napoletano. (2024) CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line. Journal of Translational Medicine 22:1.
Crossref
Mahlatse C.M. Kgokolo, Nonkululeko Z. Malinga, Helen C. Steel, Pieter W.A. Meyer, Teresa Smit, Ronald Anderson & Bernardo L. Rapoport. (2024) Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma. Translational Oncology 42, pages 101867.
Crossref
Elena Splendiani, Zein Mersini Besharat, Alessia Covre, Michele Maio, Anna Maria Di Giacomo & Elisabetta Ferretti. (2024) Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?. Pharmacology & Therapeutics 256, pages 108613.
Crossref
Junlei Hou, Xuezhi Yang, Shuanglong Xie, Bo Zhu & Haoran Zha. (2024) Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy. Frontiers in Immunology 15.
Crossref
Eun-Ji Park & Chang-Woo Lee. (2024) Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies. Experimental & Molecular Medicine 56:1, pages 100-109.
Crossref
David Digomann, Max Heiduk, Charlotte Reiche, Jessica Glück, Christoph Kahlert, Peter Mirtschink, Anna Klimova, Florian Bösch, Torsten Tonn, Jochen Gaedcke, Michael Ghadimi, Jürgen Weitz, Lena Seifert & Adrian M. Seifert. (2023) Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. npj Precision Oncology 7:1.
Crossref
Simona Serratì, Roberta Di Fonte, Letizia Porcelli, Simona De Summa, Ivana De Risi, Livia Fucci, Eustachio Ruggieri, Tommaso Maria Marvulli, Sabino Strippoli, Rossella Fasano, Tania Rafaschieri, Gabriella Guida, Michele Guida & Amalia Azzariti. (2023) Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Hidetomo Himuro, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Feifei Wei, Shun Horaguchi, Kayoko Tsuji, Yasunobu Mano, Haruhiro Saito, Koichi Azuma & Tetsuro Sasada. (2023) Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 72:8, pages 2829-2840.
Crossref
Ivan Pourmir, Alain Gey, Joséphine Pineau, Céleste Lebbe & Eric Tartour. (2023) Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes. Bulletin de l'Académie Nationale de Médecine 207:6, pages 769-778.
Crossref
Sai Pan, Wenting Zhao, Yizhan Li, Zhijun Ying, Yihong Luo, Qinchuan Wang, Xiawei Li, Wenjie Lu, Xin Dong, Yulian Wu & Xifeng Wu. (2023) Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins. Frontiers in Immunology 14.
Crossref
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos & Helen Gogas. (2023) Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers 15:10, pages 2718.
Crossref
Christina Bruss, Kerstin Kellner, Veruschka Albert, James A. Hutchinson, Stephan Seitz, Olaf Ortmann, Gero Brockhoff & Anja K. Wege. (2023) Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion. Cancers 15:9, pages 2615.
Crossref
Hisato Kawakami, Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Kenta Noda, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Hiroshi Yabusaki, Jin Matsuyama, Masazumi Takahashi, Akitaka Makiyama, Hidetoshi Hayashi, Kenji Chamoto, Tasuku Honjo, Kazuhiko Nakagawa, Wataru Ichikawa & Masashi Fujii. (2023) Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. European Journal of Cancer 184, pages 10-20.
Crossref
Christian Bailly, Xavier Thuru, Laurence Goossens & Jean-François Goossens. (2023) Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Biochemical Pharmacology 209, pages 115445.
Crossref
Vera Petrova, Christopher Groth, Rebekka Bitsch, Ihor Arkhypov, Sonja C. S. Simon, Svetlana Hetjens, Verena Müller, Jochen Utikal & Viktor Umansky. (2023) Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients. Frontiers in Immunology 14.
Crossref
Yang Li, Wenwen Wang, Jingluan Tian, Ying Zhou, Yu Shen, Mingyuan Wang, Longhai Tang, Cuiping Liu, Xueguang Zhang, Fangrong Shen, Youguo Chen & Yanzheng Gu. (2023) Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies. Technology in Cancer Research & Treatment 22.
Crossref
Kelsey E. Huntington & Wafik S. El-Deiry. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 44 .
Yumin Wu, Hui Guo, Jiawei Yue & Peng Xu. (2022) Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients. Journal of Immunology Research 2022, pages 1-10.
Crossref
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, Chiara Napoletano, Angelica Pace, Hassan Rahimi, Andrea Botticelli, Aurelia Rughetti, Marianna Nuti & Ilaria Grazia Zizzari. (2022) Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 23:22, pages 14496.
Crossref
Nna-Emeka Onukwugha, Yoon-Tae Kang & Sunitha Nagrath. (2022) Emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology: from target specific isolations to immunomodulation. Lab on a Chip 22:18, pages 3314-3339.
Crossref
Natalia Sauer, Wojciech Szlasa, Laura Jonderko, Małgorzata Oślizło, Dominika Kunachowicz, Julita Kulbacka & Katarzyna Karłowicz-Bodalska. (2022) LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. International Journal of Molecular Sciences 23:17, pages 9958.
Crossref
Yang Chen, Keren Jia, Yu Sun, Cheng Zhang, Yilin Li, Li Zhang, Zifan Chen, Jiangdong Zhang, Yajie Hu, Jiajia Yuan, Xingwang Zhao, Yanyan Li, Jifang Gong, Bin Dong, Xiaotian Zhang, Jian Li & Lin Shen. (2022) Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nature Communications 13:1.
Crossref
Ewald Jan Doornebal, Nicola Harris, Antonio Riva, Ravi Jagatia, Michail Pizanias, Andreas Prachalias, Krishna Menon, Melissa Preziosi, Ane Zamalloa, Rosa Miquel, Yoh Zen, Michael Robert Orford, Simon Eaton, Nigel Heaton, John Ramage, Elena Palma, Rajaventhan Srirajaskanthan & Shilpa Chokshi. (2022) Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment. Frontiers in Endocrinology 13.
Crossref
Jesper Pedersen, Mateo Sokac, Boe Sørensen, Adam Luczak, Ninna Aggerholm-Pedersen, Nicolai Birkbak, Trine Øllegaard & Martin Jakobsen. (2022) Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. Cancers 14:14, pages 3342.
Crossref
Nonkululeko Z. Malinga, Shalete C. Siwele, Helen C. Steel, Luyanda L.I. Kwofie, Pieter W.A. Meyer, Teresa Smit, Ronald Anderson, Bernardo L. Rapoport & Mahlatse C.M. Kgokolo. (2022) Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma. Translational Oncology 19, pages 101384.
Crossref
Jessica Thornton, Gagan Chhabra, Chandra K. Singh, Glorimar Guzmán-Pérez, Carl A. Shirley & Nihal Ahmad. (2022) Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. Frontiers in Oncology 12.
Crossref
Chao Liu, Xiaohui Li, Aijie Li, Wenxue Zou, Rui Huang, Xiaoyu Hu, Jinming Yu, Xiaoling Zhang & Jinbo Yue. (2022) Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer. Journal of Immunology Research 2022, pages 1-8.
Crossref
Simona Serratì, Michele Guida, Roberta Di Fonte, Simona De Summa, Sabino Strippoli, Rosa Maria Iacobazzi, Alessandra Quarta, Ivana De Risi, Gabriella Guida, Angelo Paradiso, Letizia Porcelli & Amalia Azzariti. (2022) Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Molecular Cancer 21:1.
Crossref
Pengxiang Yang, Yong Peng, Yuan Feng, Zhuoying Xu, Panfeng Feng, Jie Cao, Ying Chen, Xiang Chen, Xingjian Cao, Yumin Yang & Jing Jie. (2021) Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy. Frontiers in Immunology 12.
Crossref
Sabrina Adorisio, Lorenza Cannarile, Domenico V. Delfino & Emira Ayroldi. (2021) Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?. Cells 10:9, pages 2333.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.